NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$84.26 +1.91 (+2.32 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$84.26
Today's Range$81.01 - $84.55
52-Week Range$41.67 - $86.10
Volume980,469 shs
Average Volume636,059 shs
Market Capitalization$4.10 billion
P/E Ratio-11.23
Dividend YieldN/A
Beta1.97
Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Debt-to-Equity RatioN/A
Current Ratio10.10
Quick Ratio10.06

Price-To-Earnings

Trailing P/E Ratio-11.23
Forward P/E Ratio-15.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.61 million
Price / Sales1,606.75
Cash FlowN/A
Price / CashN/A
Book Value$8.68 per share
Price / Book9.71

Profitability

EPS (Most Recent Fiscal Year)($7.50)
Net Income$-302,130,000.00
Net MarginsN/A
Return on Equity-46.22%
Return on Assets-39.24%

Miscellaneous

Employees520
Outstanding Shares49,770,000

The Truth About Cryptocurrencies

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released its quarterly earnings results on Monday, May, 7th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.81. The biopharmaceutical company earned $10.68 million during the quarter, compared to the consensus estimate of $56.58 million. During the same quarter last year, the firm earned ($1.63) EPS. View Ultragenyx Pharmaceutical's Earnings History.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Ultragenyx Pharmaceutical.

What price target have analysts set for RARE?

21 brokerages have issued 1 year price targets for Ultragenyx Pharmaceutical's shares. Their forecasts range from $55.00 to $83.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $71.2632 in the next twelve months. View Analyst Ratings for Ultragenyx Pharmaceutical.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (1/30/2018)
  • 2. JPMorgan Chase & Co. analysts commented, "RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline." (11/5/2017)
  • 3. Cowen Inc analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)

Who are some of Ultragenyx Pharmaceutical's key competitors?

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:
  • Dr. Emil D. Kakkis, Pres, CEO & Director (Age 58)
  • Ms. Shalini Sharp, CFO & Exec. VP (Age 43)
  • Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 58)
  • Mr. John Richard Pinion II, Chief Quality Officer & Exec. VP of Translational Sciences (Age 52)
  • Dr. Jayson Donald Alexander Dallas, Chief Commercial Officer & Exec. VP (Age 50)

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

News stories about RARE stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 0.13 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.24 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.51%), Federated Investors Inc. PA (2.41%), Northern Trust Corp (1.04%), Millennium Management LLC (0.60%), Schwab Charles Investment Management Inc. (0.45%) and Rock Springs Capital Management LP (0.35%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Legal & General Group Plc, Prudential Financial Inc., Point72 Asset Management L.P., Opaleye Management Inc., C WorldWide Group Holding A S, Smith Asset Management Group LP, Teacher Retirement System of Texas and California Public Employees Retirement System. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Federated Investors Inc. PA, UBS Group AG, Kornitzer Capital Management Inc. KS, Northern Trust Corp, Schwab Charles Investment Management Inc. and Highbridge Capital Management LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $84.26.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $4.10 billion and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-302,130,000.00 in net income (profit) each year or ($7.50) on an earnings per share basis. Ultragenyx Pharmaceutical employs 520 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]


MarketBeat Community Rating for Ultragenyx Pharmaceutical (RARE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  527 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  733
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.